Visara Secures Exclusive Option for Potential Acquisition of YOL104-2 for Ocular Surface Squamous Neoplasia
Visara, the majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), secured an exclusive option to acquire worldwide rights to the YOL104 Program, including YOL104-2, from YOLO Immune. YOL104-2 is a trivalent interferon-alpha peptibody in investigation for ocular surface squamous neoplasia, an ocular surface cancer with no FDA-approved therapy today.
Key figures
- Drug Name
- YOL104-2
- Financial terms
- not disclosed (upfront option payment, exercise payment, milestones, tiered royalties)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.